22 May 2013
Keywords: biogen, idec, amevive, oked, australia, biotechnology, firm
Article | 28 June 2004
US biotechnology firm Biogen Idec says that the Therapeutic Goods Administration has approved its Amevive (alefacept) for sale in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 June 2004
5 July 2004
21 May 2013
© 2013 thepharmaletter.com